Payam Tabarsi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6669876/publications.pdf Version: 2024-02-01



DAVAM TARADSI

#	Article	IF	CITATIONS
1	Smell dysfunction: a biomarker for COVIDâ€19. International Forum of Allergy and Rhinology, 2020, 10, 944-950.	2.8	616
2	Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli. Chest, 2009, 136, 420-425.	0.8	524
3	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, The, 2018, 392, 821-834.	13.7	452
4	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
5	Cancers Related to Immunodeficiencies: Update and Perspectives. Frontiers in Immunology, 2016, 7, 365.	4.8	137
6	Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis. Journal of Clinical Immunology, 2015, 35, 1-10.	3.8	129
7	Differences in Cell Wall Thickness between Resistant and Nonresistant Strains of <i>Mycobacterium tuberculosis</i> : Using Transmission Electron Microscopy. Chemotherapy, 2009, 55, 303-307.	1.6	115
8	Diabetes mellitus and tuberculosis facts and controversies. Journal of Diabetes and Metabolic Disorders, 2013, 12, 58.	1.9	90
9	Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. European Journal of Gastroenterology and Hepatology, 2010, 22, 1235-1238.	1.6	87
10	Prevalence and reversibility of smell dysfunction measured psychophysically in a cohort of COVIDâ€19 patients. International Forum of Allergy and Rhinology, 2020, 10, 1127-1135.	2.8	81
11	COVID-19 and Substance Use Disorders as Brain Diseases: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. Basic and Clinical Neuroscience, 2020, 11, 133-150.	0.6	74
12	First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance. International Journal of Infectious Diseases, 2009, 13, e236-e240.	3.3	69
13	Inherited disorders of the IL-12-IFN-Î ³ axis in patients with disseminated BCG infection. European Journal of Pediatrics, 2005, 164, 753-757.	2.7	59
14	Adverse Effects of Multidrug-Resistant Tuberculosis Treatment With a Standardized Regimen: A Report From Iran. American Journal of Therapeutics, 2011, 18, e29-e34.	0.9	51
15	Lethal Tuberculosis in a Previously Healthy Adult with IL-12 Receptor Deficiency. Journal of Clinical Immunology, 2011, 31, 537-539.	3.8	49
16	Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal of Infectious Diseases, 2005, 9, 317-322.	3.3	44
17	The Recent-Transmission of Mycobacterium tuberculosis Strains among Iranian and Afghan Relapse Cases: a DNA-fingerprinting using RFLP and spoligotyping. BMC Infectious Diseases, 2008, 8, 109.	2.9	43
18	Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases. American Journal of Therapeutics, 2010, 17, 17-22.	0.9	43

PAYAM TABARSI

#	Article	IF	CITATIONS
19	Nontuberculous Mycobacteria Among Patients Who are Suspected for Multidrug-Resistant Tuberculosis—Need for Earlier Identification of Nontuberculosis Mycobacteria. American Journal of the Medical Sciences, 2009, 337, 182-184.	1.1	35
20	High Prevelance of Rifampin-Monoresistant Tuberculosis: A Retrospective Analysis among Iranian Pulmonary Tuberculosis Patients. American Journal of Tropical Medicine and Hygiene, 2014, 90, 99-105.	1.4	33
21	Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology, 2021, 27, 486-492.	2.1	33
22	Primary Immune Deficiencies Presenting in Adults: Seven Years of Experience from Iran. Journal of Clinical Immunology, 2005, 25, 385-391.	3.8	28
23	Vulnerability of Homeless People in Tehran, Iran, to HIV, Tuberculosis and Viral Hepatitis. PLoS ONE, 2014, 9, e98742.	2.5	26
24	Factors associated with death or intensive care unit admission due to pandemic 2009 influenza A (H1N1) infection. Annals of Thoracic Medicine, 2011, 6, 91.	1.8	25
25	Trends of drug resistant Mycobacterium tuberculosis in a tertiary tuberculosis center in Iran. Journal of King Abdulaziz University, Islamic Economics, 2007, 28, 544-50.	1.1	25
26	Common Infections and Target Organs Associated with Chronic Granulomatous Disease in Iran. International Archives of Allergy and Immunology, 2019, 179, 62-73.	2.1	24
27	Pattern recognitions receptors in immunodeficiency disorders. European Journal of Pharmacology, 2017, 808, 49-56.	3.5	23
28	Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. Microbial Drug Resistance, 2010, 16, 81-86.	2.0	22
29	Mendelian Susceptibility to Mycobacterial Disease (MSMD): Clinical and Genetic Features of 32 Iranian Patients. Journal of Clinical Immunology, 2020, 40, 872-882.	3.8	22
30	Performance of QuantiFERON-TB Gold test compared to tuberculin skin test in detecting latent tuberculosis infection in HIV- positive individuals in Iran. Annals of Thoracic Medicine, 2010, 5, 43.	1.8	22
31	Nocardiosis: Risk Factors, Clinical Characteristics and Outcome. Iranian Red Crescent Medical Journal, 2013, 15, 436-9.	0.5	22
32	Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. International Journal of Clinical and Experimental Medicine, 2010, 3, 308-14.	1.3	22
33	Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iranian Journal of Pharmaceutical Research, 2016, 15, 247-52.	0.5	21
34	Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia. Indian Journal of Critical Care Medicine, 2012, 16, 141-147.	0.9	20
35	Elevated CXCL-8 expression in bronchoalveolar lavage correlates with disease severity in patients with acute respiratory distress syndrome resulting from tuberculosis. Journal of Inflammation, 2014, 11, 21.	3.4	19
36	Isoniazid Blood Levels in Patients with Pulmonary Tuberculosis at a Tuberculosis Referral Center. Chemotherapy, 2011, 57, 7-11.	1.6	18

PAYAM TABARSI

#	Article	IF	CITATIONS
37	Revised Category II Regimen as an Alternative Strategy for Retreatment of Category I Regimen Failure and Irregular Treatment Cases. American Journal of Therapeutics, 2011, 18, 343-349.	0.9	17
38	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. Journal of Global Antimicrobial Resistance, 2016, 4, 1-4.	2.2	17
39	Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. International Journal of Infectious Diseases, 2010, 14, e399-e402.	3.3	16
40	Utility of gastric lavage for diagnosis of tuberculosis in patients who are unable to expectorate sputum. Journal of Global Infectious Diseases, 2011, 3, 339.	0.5	15
41	Combination therapy of IFNβ1 with lopinavir–ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. International Immunopharmacology, 2021, 92, 107329.	3.8	15
42	Impact of HIV infection on tuberculous pleural effusion. International Journal of STD and AIDS, 2016, 27, 363-369.	1.1	14
43	Paecilomyces formosus Infection in an Adult Patient with Undiagnosed Chronic Granulomatous Disease. Journal of Clinical Immunology, 2017, 37, 342-346.	3.8	13
44	Chronic Granulomatous Disease with Unusual Clinical Manifestation, Outcome, and Pattern of Inheritance in an Iranian Family. Journal of Clinical Immunology, 2006, 26, 291-296.	3.8	12
45	Proteomic and genomic biomarkers for Nonâ€Small Cell Lung Cancer: Peroxiredoxin, Haptoglobin, and Alphaâ€1 antitrypsin. Cancer Medicine, 2020, 9, 3974-3982.	2.8	10
46	Extensively Drug-Resistant Tuberculosis: A Review Article. Archives of Clinical Infectious Diseases, 2012, 7, 81-4.	0.2	10
47	Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 138-142.	0.6	10
48	Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. Scandinavian Journal of Infectious Diseases, 2009, 41, 10-13.	1.5	7
49	The Effect of Garcin® in Preventing AntiTB-Induced Hepatitis in Newly Diagnosed Tuberculosis Patients. Iranian Journal of Pharmaceutical Research, 2014, 13, 169-76.	0.5	7
50	Representative drug susceptibility patterns for guiding design of reâ€treatment regimens for multidrugâ€resistant tuberculosis in Iran. Respirology, 2008, 13, 108-111.	2.3	5
51	Do mitochondrial DNA haplogroups play a role in susceptibility to tuberculosis?. Respirology, 2007, 12, 823-827.	2.3	4
52	Differences in characteristics between Afghani and Iranian patients with pulmonary tuberculosis. International Journal of Infectious Diseases, 2007, 11, 180-182.	3.3	3
53	Secondary infection and clinical aspects after pandemic swine-origin influenza a (H1N1) admission in an Iranian critical care unite. International Journal of Critical Illness and Injury Science, 2014, 4, 309.	0.6	3
54	Investigating PIKR and ATpA Genes Expressions in Ventilator-Associated Pneumonia Patients Admitted to the Intensive Care Unit of Masih Daneshvari Hospital in 2016. Reports of Biochemistry and Molecular Biology, 2018, 6, 118-124.	1.4	3

PAYAM TABARSI

#	Article	IF	CITATIONS
55	Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran. Tanaffos, 2020, 19, 122-128.	0.5	3
56	Acute Necrotizing Pneumonia in a Previously Healthy Young Adult. Clinical Infectious Diseases, 2008, 46, 266-267.	5.8	2
57	Association of <i>Mycobacterium</i> infections in patients with Mendelian susceptibility to mycobacterial disease with venous thromboembolism. Microbiology and Immunology, 2016, 60, 678-686.	1.4	2
58	Recurrent Drug-Induced Hepatitis in Tuberculosis—Comparison of Two Drug Regimens. American Journal of Therapeutics, 2017, 24, e144-e149.	0.9	2
59	Disseminated Mycobacterium kansasii in an HIV-negative patient. International Journal of Mycobacteriology, 2012, 1, 51-52.	0.6	1
60	First report of occurrence of Mycobacterium tuberculosis and Non-tuberculous mycobacteria in a heterozygous carrier of chronic granulomatous patient. International Journal of Mycobacteriology, 2015, 4, 150.	0.6	1
61	Estimation of Ten-Year Survival of Patients with Pulmonary Tuberculosis Based on the Competing Risks Model in Iran. Tanaffos, 2016, 15, 37-43.	0.5	1
62	Trends in multidrug-resistant tuberculosis in Tehran, Iran: an analysis of published data. GMS Hygiene and Infection Control, 2019, 14, Doc11.	0.3	1
63	Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients. Tanaffos, 2020, 19, 291-299.	0.5	1
64	SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran. Frontiers in Public Health, 2022, 10, 832003.	2.7	1
65	A Young Woman with Diffuse Skin Lesions. Clinical Infectious Diseases, 2010, 51, 248-249.	5.8	0
66	Anti-tuberculosis drug concentrations and treatment outcomes among HIV-infected patients with tuberculosis. HIV and AIDS Review, 2018, 17, 111-116.	0.2	0
67	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Review Article. Archives of Pediatric Infectious Diseases, 2014, 3, .	0.3	0
68	Augmented Renal Clearance in Iranian Critically III Patients: Retrospective Study at Masih Daneshvari Hospital. Archives of Critical Care Medicine, 2017, In Press, .	0.0	0
69	Management of MDR-TB: Review of Iran's Experience. Tanaffos, 2013, 12, 6-15.	0.5	0
70	Etiology of Respiratory Complications among Iranian HIV Infected Patients. Tanaffos, 2019, 18, 96-103.	0.5	0